SURMOUNT-5 Trial Summary: Tirzepatide vs Semaglutide Head-to-Head

Design

Randomized, open-label, head-to-head phase 3b trial comparing tirzepatide (maximum tolerated dose, up to 15 mg weekly) with semaglutide (maximum tolerated dose, up to 2.4 mg weekly) in 751 adults with BMI ≥30 (or ≥27 with weight-related comorbidity). Duration: 72 weeks.

The open-label design reflects the practical reality that both drugs are commercially available and patients know which they are taking. Primary endpoint: percent change in body weight at week 72.

Primary result

Mean body-weight change at 72 weeks:

• Tirzepatide: −20.2%
• Semaglutide: −13.7%

Estimated treatment difference: −6.5 percentage points (P < 0.001).

Tirzepatide produced approximately 47% greater weight loss than semaglutide at maximum tolerated doses.

Key secondary outcomes

• ≥5% weight loss: Tirzepatide 94.4% vs. semaglutide 85.0%
• ≥10% weight loss: Tirzepatide 82.8% vs. semaglutide 67.7%
• ≥15% weight loss: Tirzepatide 68.8% vs. semaglutide 44.2%
• ≥20% weight loss: Tirzepatide 51.5% vs. semaglutide 26.1%
• Waist circumference reduction: Greater with tirzepatide (−16.8 cm vs. −12.3 cm)

Tolerability

Gastrointestinal adverse events were common in both groups but slightly higher with tirzepatide:

• Nausea: Tirzepatide 33.3% vs. semaglutide 29.2%
• Diarrhea: Tirzepatide 21.0% vs. semaglutide 18.2%
• Vomiting: Tirzepatide 15.2% vs. semaglutide 13.1%

Discontinuation rates for adverse events were comparable between groups (~6–8%).

Interpretation

SURMOUNT-5 established tirzepatide's superiority over semaglutide for weight loss — the first head-to-head demonstration. The clinical significance:

1. Dual agonism matters — tirzepatide's GLP-1/GIP dual agonism produces meaningfully greater weight loss than GLP-1 agonism alone. This validates the multi-agonist approach and suggests GIP receptor activation contributes incremental efficacy beyond GLP-1
2. The 20% threshold — tirzepatide crossed the clinically significant 20% mean weight-loss threshold that was previously considered achievable only with bariatric surgery
3. Individual variation is large — despite group means, individual responses varied substantially. Some semaglutide responders achieved results equivalent to tirzepatide, and some tirzepatide non-responders had modest results. Drug selection should account for individual response, tolerability, and access
4. Open-label limitation — the lack of blinding means expectation effects cannot be excluded. Participants knowing they were on the "newer" drug could influence adherence and lifestyle behaviors. However, the magnitude of difference (6.5 percentage points) likely exceeds what expectation alone could produce

Clinical significance

For patients and clinicians choosing between the two leading weight-loss drugs, SURMOUNT-5 provides the direct comparison data that was previously lacking. Tirzepatide is the more effective drug on average, but cost, availability, insurance coverage, and individual tolerability remain important practical considerations in real-world prescribing.